The pharmacokinetics (PK) and pharmacodynamics (PD) of cefotaxime and ofloxacin and of their combination were examined in a three-period randomized crossover study involving 12 healthy adults. The PK of cefotaxime and ofloxacin were modeled. PD was assessed from the predicted concentrations in serum and serum untrafiltrate inhibitory titers for 10 test organisms. An inhibitory sigmoid E max model based on the probability of bacterial growth was used, where Emax ‫؍‬ 1 and EC 50 is the concentration resulting in a 50% probability of growth. The total body clearance (CL T ) and volume of distribution at steady state (V SS ) Combinations of antimicrobial agents are often preferred to single agents for the treatment of serious infections (11, 28) . These combinations may provide a broader antibacterial spectrum and more-rapid bacterial killing than single agents. Problems with resistance emerging during therapy may be minimized when combinations are used. Resistance may result from the initial presence of a resistant subpopulation or from bacterial mutations. In either case, resistance to two drugs is less common than resistance to a single agent. Although aminoglycosides have been traditionally combined with ␤-lactam agents, fluoroquinolone-␤-lactam combinations have been used with increasing frequency (6, 12, 16, 20, 23, 24) . These reports have usually involved combinations of ciprofloxacin and extended-spectrum penicillins (6, 12, 23, 24) .
Combinations of antimicrobial agents are often preferred to single agents for the treatment of serious infections (11, 28) . These combinations may provide a broader antibacterial spectrum and more-rapid bacterial killing than single agents. Problems with resistance emerging during therapy may be minimized when combinations are used. Resistance may result from the initial presence of a resistant subpopulation or from bacterial mutations. In either case, resistance to two drugs is less common than resistance to a single agent. Although aminoglycosides have been traditionally combined with ␤-lactam agents, fluoroquinolone-␤-lactam combinations have been used with increasing frequency (6, 12, 16, 20, 23, 24) . These reports have usually involved combinations of ciprofloxacin and extended-spectrum penicillins (6, 12, 23, 24) .
Cefotaxime plus ofloxacin was compared to cefotaxime plus tobramycin treatment in cancer patients with fever and symptoms of serious infection (20) . A statistically improved cure rate for the cefotaxime-ofloxacin combination (71%) compared to that for the cefotaxime-tobramycin combination (47%) was observed. Synergy or partial synergy was also demonstrated in 89 of 110 gram-negative isolates when a 1:1 ratio of cefotaxime and desacetylcefotaxime was combined with ofloxacin (13) . For gram-positive organisms, 81 of 89 isolates showed synergy or partial synergy by the checkerboard method. However, the 1:1 ratio of desacetylcefotaxime to cefotaxime is somewhat higher than the ratio reported in pharmacokinetic (PK) studies.
In this study, serum ultrafiltrate inhibitory titers (uSITs) from healthy volunteers given cefotaxime alone, ofloxacin alone, and the combination of cefotaxime and ofloxacin in a crossover study were measured. The objective of this study was to determine the interactions of pharmacokinetics (PK) and pharmacodynamics (PD) between cefotaxime and ofloxacin.
MATERIALS AND METHODS
A protocol was developed and approved by the institutional review board. Informed consent was obtained from all participants. Twelve healthy subjects were enrolled in this three-period crossover study involving cefotaxime and ofloxacin given alone and in combination. Subjects were male or female and were aged between 18 and 40 years. A serum pregnancy test was performed on all female subjects, and the result was required to be negative. No other drugs were permitted within 1 week of the study, except for previously prescribed oral contraceptives. Barrier contraceptive methods were recommended to all females, including those using oral contraceptives.
Subjects were confined to the research center for 3 days during each of three treatment phases. The treatment phases consisted of 2 g of cefotaxime every 8 h (treatment A), 400 mg of ofloxacin every 12 h (treatment B), and a combination of cefotaxime and ofloxacin with the same dosages (treatment C). Each antimicrobial agent was administered for five doses at times that would provide a wide range of the cefotaxime-ofloxacin concentration ratio. Cefotaxime was administered at 0830 and 1630 on day 2 and at 0030, 0830, and 1630 on day 3 for treatments A and C. Ofloxacin was administered at 1900 on day 1 and at 0700 and 1900 on days 2 and 3 during treatments B and C. All doses were administered by constant rate infusion with intravenous (i.v.) pumps over a period of 0.5 h for cefotaxime and 1 h for ofloxacin. The same dosing times were used for the combination regimen. Administration times were staggered at intervals of 4 min. As a consequence, all infusions were started within 50 min following the stated times and remained constant for a particular subject. The administration times for cefotaxime relative to ofloxacin remained fixed for all subjects.
The primary outcome measurements included concentrations of cefotaxime and ofloxacin in serum and serum ultrafiltrate inhibitory activity. Blood samples were collected during day 3 for all treatment phases at 0800, 0900, 1000, 1100, 1200, 1600, 1700, 1800, 2000, and 2100. As with dosing times, sampling times for individual subjects were within 50 min following the stated times and were constant relative to dosing times. During treatments A and B, two 7-ml blood samples were obtained, one for drug concentration, and one for uSIT measurement. Three 7-ml samples were obtained at each time for treatment C (one for ofloxacin concentration, one for cefotaxime concentration, and one for uSIT measurement). The samples were allowed to clot at ambient temperature for 30 min. Following centrifugation at 2,500 ϫ g, the serum was removed and frozen at Ϫ70°C.
Ofloxacin, cefotaxime, and desacetyl-cefotaxime concentrations in serum were determined by specific reverse-phase high-performance liquid chromatography assays developed and validated at the Clinical Pharmacokinetics Laboratory. Quantitation ranges were defined by the linear region of a standard curve where the minimal quantifiable concentration (MQC) exhibits a peak height of approximately 10 times the baseline noise amplitude. Minimum detectable concentrations (MDC) were 2 to 2.5 times less than the MQC; however, these concentrations were not used in the PK analysis. Validation was performed over 5 days prior to performing analysis of study samples. The reported assay variability was obtained from quality control samples that were run during the period in which study samples were analyzed and represents a combined intra-and interday coefficient of variation (CV). CVs during the validation phase were similar to and often lower than those during the study phase. For cefotaxime, concentrations were quantitated from 0.50 to 100 g/ml. CVs for quality control samples were 6.9% at 2.00 g/ml, 5.7% at 15.0 g/ml, 6.9% at 75.0 g/ml, and 8.6% at 240 g/ml. For concentrations that were greater than 100 g/ml, samples were diluted two-to fourfold with buffer and then reassayed. For desacetylcefotaxime, concentrations were quantitated from 0.43 to 17.2 g/ml. CVs for quality control samples were 6.0% at 1.72 g/ml, 5.4% at 6.89 g/ml, and 6.5% at 13.8 g/ml. Concentrations of ofloxacin were quantitated from 0.10 to 10.0 g/ml. CVs for quality control samples were 4.4% at 7.00 g/ml, 4.4% at 1.4 g/ml, and 5.3% at 0.35 g/ml.
Serum inhibitory activity studies were performed on the serum ultrafiltrate by published methods (18) . Serum was ultrafiltered through a Centrifree micropartition system YMT membrane (Amicon, Beverly, Mass.) by centrifugation for 30 min at 1,000 ϫ g at room temperature. A control sample containing cefotaxime or ofloxacin (alternating) in media was included in each assay plate to monitor the uSIT testing. With sterile Mueller-Hinton cation-adjusted broth, serial dilutions were performed to provide serum ultrafiltrate dilutions ranging from 1:2 to 1:1,024. All studies were performed by using 96-well microdilution trays with a final volume of 0.1 ml per well. The test organisms included two strains each of Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Data analysis. PK-PD analysis was accomplished by a three-step analysis and Adapt II (release 3) software (4a). The first step involved PK analysis of the ofloxacin and cefotaxime data. Models were selected on the basis of prior data (cefotaxime) and goodness of fit. A one-compartment model was clearly inappropriate given the concentration-time curve shape. More-complex models were not needed based on examination or residuals. In addition, the number of available data points would not support a three-compartment model. For cefotaxime, a two-compartment i.v. intermittent infusion model was used with the MAP Bayesian algorithm of Adapt II. The Bayesian parameter mean estimates (CV%), which were derived from unpublished data were as follows: total body clearance (CL T ), 23.7 (30%) liters/h; volume of central compartment (V c ), 7.6 (100%) liters; distributional clearance (CL D ), 34.4 (150%) liters/h, and volume of peripheral compartment (V p ), 11.7 (50%) liters. The variance estimates were set higher than the actual data to ensure that individual parameter estimates were not constrained. Since we did not have similar prior data for ofloxacin, fitting was accomplished by using the weighted least-squares algorithm of Adapt II. For both drugs, fitted concentrations were weighted by 1/assay variance, assuming a linear relationship between standard deviation (SD) and concentration. A positive intercept (1/2 ϫ MDC) was always included to allow increasing variability at low concentration. The PK of desacetylcefotaxime was summarized descriptively by assuming steady state and combining data for both dosing intervals. Reported parameters included minimum and maximum concentrations and area under the plasma concentration-time curve from 0 to 8 h (AUC 0-8 ). The trapezoidal rule was used to determine the AUC 0-8 .
Step two of the analysis involved estimating the PD parameters for individual drugs. Desacetylcefotaxime was not initially considered in the PD modeling of cefotaxime. Growth-no growth data from the inhibitory activity study and the drug concentrations predicted by the model were assessed at each time point. Individual PK parameters from step one were used as fixed parameters for step two to determine the predicted drug concentrations. For serum ultrafiltrate inhibitory activity, data from 10 wells with dilutions ranging from 1:2 to 1:1,024 were available. The probability of growth was modeled by using an inhibitory sigmoid E max model. Data from the entire row of serum ultrafiltrate dilutions were modeled such that probabilities of growth were coded 0 for no growth and 1 for growth. The equation used was
where EC 50 is the concentration of drug resulting in a 50% probability of growth, h is the sigmoidicity factor, C is the model-predicted concentration of drug, and F is the dilution factor for each well. For an individual, a total of 10 samples were assessed for inhibitory activity, and 10 dilutions were performed for each sample. Thus, 100 data points were considered in the estimation of EC 50 and h values for each subject. Each subject had estimated EC 50 values for cefotaxime and ofloxacin that were organism specific. The results of uSIT are comparable to the results of SITs, since free drug accounts for most of the activity (18 (21) and 47 to 50% (4), respectively. Protein binding has been shown not to affect the activity of cefotaxime in SIT and bactericidal titer studies (15) . The combination of cefotaxime and ofloxacin was evaluated to determine the type of PD interaction. Prior estimates of pharmacokinetic parameters from the first step and EC 50 s of the monotherapies from the second step were used as fixed parameters. The probability of growth was modeled as
where D is equal to C/EC 50 (for cefotaxime) ϩ C/EC 50 (for ofloxacin) and is an interaction term. The sigmoidicity parameters for the two monotherapies and for the combination were re-estimated during this step. Parameter estimates in Adapt II are restricted to positive numbers. To accommodate negative numbers, 10 was coded as 10 p(1) /1,000, where p(1) is a parameter serving as an intermediate for . Once estimated, p(1) was transformed to by subtracting 3 from the value of p (1) . Each subject-test organism combination has a unique estimate of .
Our definition of synergy or antagonism was consistent with conventions that are used in the checkerboard method of in vitro synergy testing. The fractional inhibitory concentration (FIC) index is equal to
as defined by the drug concentrations in the greatest dilution(s) of the serum or medium sample that inhibits bacterial growth, where A and B represent individual drugs (5) . Synergy and antagonism are defined as FIC indices of Յ0.25 and Ͼ4, respectively. In addition, there is an intermediate region with FIC indices of 0.25 to Յ0.5, termed possible or partial synergy, and with FIC indices of Ͼ2 to 4, termed possible or partial antagonism. Additivity is defined as a FIC index of between Ͼ0.5 and 2. To determine the meaning of , several checkerboard panels (8 by 8) were simulated with the PD model described above. For each case, 64 concentration pairs of cefotaxime and ofloxacin were generated. MICs for cefotaxime and ofloxacin varied in different cases, as did the ratios of concentrations of cefotaxime to ofloxacin. The sigmoidicity factor was fixed at 5, which was consistent with the fitted values in this study. Then, for each simulation case, the value of was changed at 0.1 intervals between 4 and Ϫ4. For each concentration pair, the probability of growth was calculated and rounded to 0 (no growth) or 1 (growth) if the probability was Յ0.5 or Ͼ0.5, respectively. The FIC index was determined for the simulated checkerboard panel and tabulated with corresponding values of . This analysis revealed that values ranging from Ϫ0.3 to 0.3 are consistent with additivity. Values of of less than Ϫ0.6 are consistent with synergy, while values ranging from Ϫ0.6 to Ϫ0.3 represent possible synergy. Antagonism is defined by values of greater than 0.6, and possible antagonism is defined by values ranging from 0.3 to 0.6. Area under the ultrafiltrate inhibitory activity versus time curve (AUIC) was calculated by the linear trapezoidal rule for the 14-h period when uSIT measurements were made. These values, which were intended to compare combination treatment with monotherapy, were referred to as the 14-h AUIC to reflect their origin from measured inverse uSITs. Theoretically, the measured uSIT can be predicted from drug concentration divided by the MIC. To test this theorem, we determined the predicted AUC/MIC for the same 14-h period. The predicted 14-h AUC/MIC was calculated as the AUC divided by the MIC for a particular pathogen. The 14-h AUC was calculated by model integration with subjectspecific PK parameters. The MIC used was the geometric mean MIC obtained from three replicates per day for 5 days. Comparisons between the AUIC and the predicted AUC/MIC were made by linear regression of the log-transformed values. For the combination treatment, the predicted activity was defined as the sum of predicted AUC/MIC values for the two drugs. Since the 24-h AUC/MIC is most often discussed in the literature, we also calculated this parameter for each treatment regimen. For the two monotherapy regimens, predicted 24-h AUC/MIC values were calculated from the PK parameters and EC 50 s. AUC 0-at steady state, where is the dosing interval in hours, was determined directly from the PK model and parameter estimates for one steady-state dosing interval. The 24-h AUC was determined by AUC 24 ϭ (AUC 0-) ϫ 24/. Assuming additivity, AUC/MIC 24 for the combination is the sum of the two monotherapy AUC/MIC 24 values.
Time above MIC is particularly important for ␤-lactam agents. Consequently, time above MIC was determined by simulating the concentrations of cefotaxime and ofloxacin. The administration times used in simulations were the same as those used in the study. Additivity was assumed and therefore the total inhibitory activity is defined by C/EC 50 (for cefotaxime) ϩ C/EC 50 (for ofloxacin). Theoretically, inhibitory activity would be present when the FIC Ն1 (5). Simulations for each organism were done according to subject by using PK parameters and EC 50 values for cefotaxime and ofloxacin. For monotherapy regimens, FIC is equivalent to C/EC 50 for the individual drug. The simulations were performed for a 24-h time period, with concentrations calculated at 5-min intervals. Percent time above MIC was defined as the number of cases in which FIC or C/EC 50 was Ն1 divided by the total number of cases (288) ϫ 100%.
RESULTS
Eleven subjects completed the study. One female subject withdrew after completing two of three phases due to a skin rash. The mean age of all subjects was 27.9 (25.6%) years (26.7 years for males [n ϭ 6] and 29.4 years for females [n ϭ 5]). The mean body weights were 72.8 (12.8%) kg overall (77.7 kg for males and 66.9 kg for females). The mean height was 172 cm for all subjects. Mean heights were higher for males (179 cm) than for females (164 cm).
Both cefotaxime and ofloxacin were well tolerated by most subjects. There were 12 adverse experiences reported during the three study phases. Headache was the most common, occurring for subjects during treatments A (n ϭ 1), B (n ϭ 2), and C (n ϭ 1). One subject reported myalgia in the neck region during cefotaxime treatment. There were two cases of local venous irritation during treatments B (n ϭ 1) and C (n ϭ 1). One subject reported nausea during the ofloxacin treatment. He also reported contact dermatitis due to adhesive tape during the combination treatment and mild pharyngitis (presumed viral) before and during cefotaxime treatment. Subject no. 8 completed her combination treatment first without difficulty and then developed a generalized pruritic rash during the cefotaxime treatment. She was removed from the study due to presumed allergic reaction to cefotaxime.
Mean concentrations of cefotaxime, desacetylcefotaxime, and ofloxacin in serum for the three treatment phases are shown in Fig. 1A to C. Error bars (SD) were omitted from Fig.  1C to minimize clutter. However, the SDs were similar to those observed for the monotherapy regimens. Table 1 provides the PK parameters for ofloxacin and cefotaxime. The mean (CV%) CL T s of cefotaxime were 0.236 (18.2%) liters/kg/h when administered as monotherapy and 0.231 (19.5%) liters/kg/h when administered with ofloxacin. The mean volumes of distribution at steady state (V SS ) were 2.07 (16.9%) liters/kg for cefotaxime alone and 0.208 (13.0%) liters/kg for cefotaxime in the combination treatment. There were no differences between the two treatment regimens in terms of CL T for cefotaxime (P ϭ 0.509) or V SS for cefotaxime (P ϭ 0.853). For cefotaxime alone, male subjects had a mean CL T of 0.223 liters/kg/h and a mean V SS of 0.194 liters/kg. These values were not different from those of female subjects, who had a mean CL T of 0.251 liters/kg/h and a mean V SS of 0.221 liters/kg (P ϭ 0.326 and 0.248, respectively). Similar results were seen for cefotaxime during combination treatment. Male subjects had a mean CL T of 0.221 liters/kg/h and a mean V SS of 0.202 liters/kg, while female subjects had a mean CL T of 0.242 liters/kg/h and a mean V SS of 0.216 liters/kg. Desacetylcefotaxime was detected in all subjects with mean minimum concentrations of 0.79 g/ml (CV, 48.0%) following cefotaxime treatment and 0.82 g/ml (37.1%) following cefotaxime-ofloxacin treatment. The mean maximum concentrations of desacetylcefotaxime were 6.59 g/ml (25.8%) and 7.08 g/ml (32.1%) for the single and combination treatments, respectively. The AUC 0-8 values of desacetylcefotaxime were 25.2 g ⅐ h/ml (32.1%) for cefotaxime alone and 26.5 g ⅐ h/ml (26.2%) for cefotaxime plus ofloxacin. There were no significant differences between the two treatments in the above PK parameters for desacetylcefotaxime.
The mean CL T s of ofloxacin were 0.143 (14.7%) liters/kg/h when administered alone and 0.141 (16.3%) liters/kg/h when administered with cefotaxime. The mean V SS of ofloxacin were 1.20 (24.9%) liters/kg for the ofloxacin treatment and 1.16 (6.6%) liters/kg for the ofloxacin-cefotaxime treatment. No statistical differences in the CL T (P ϭ 0.782) or V SS (P ϭ 0.684) of ofloxacin were observed when comparing ofloxacin administered with and without cefotaxime. For ofloxacin alone, male subjects had a mean CL T of 0.144 liters/kg/h and a mean V SS of 1.15 liters/kg. These values were not different from those of female subjects, who had a mean CL T of 0.142 liters/kg/h and a mean V SS of 1.25 liters/kg (P ϭ 0.901 and 0.629, respectively). During the combination treatment, male subjects had a mean CL T of 0.145 liters/kg/h and a mean V SS of 1.19 liters/kg, while female subjects had a mean CL T of 0.137 liters/kg/h and a mean V SS of 1.12 liters/kg. There were no differences in CL T and V SS with regard to sex (P ϭ 0.612 and 0.133, respectively).
The test organisms exhibited geometric mean MICs ranging from 0.239 to 18.4 g/ml for cefotaxime and 0.122 to 1.66 g/ml for ofloxacin. Table 2 lists the median MICs and mean EC 50 s for cefotaxime and ofloxacin. As expected, EC 50 s were similar to the geometric mean MICs for the two drugs. Linear regression of log MIC versus log EC 50 for cefotaxime yielded the line y ϭ 0.987 ⅐ x Ϫ 0.096 (r 2 ϭ 0.946). For ofloxacin, the regression line was y ϭ 0.941 ⅐ x Ϫ 0.169 (r 2 ϭ 0.88). The measured uSITs were summarized for the individual drugs and the combination by using a 14-h AUIC. Fourteen hours was used, since this was the period of time when assessments for inhibitory activity were made. These AUIC values can be used to compare the monotherapies to the combination therapy. Table 3 shows the mean (CV%) AUIC values for cefotaxime, ofloxacin, and the combination of cefotaxime and ofloxacin. In this study, cefotaxime and ofloxacin were administered every 8 h and 12 h, respectively. The administration times were designed to provide a broad range of cefotaximeofloxacin concentration ratios, thus improving the ability to evaluate the type of interaction.
Differences between measured and predicted 14-h AUICs were evaluated by using a log ratio, ln [AUIC/(AUC/MIC)] by subject and organism. The overall log ratios were 1.03 for cefotaxime (P ϭ 0.01), 0.899 for ofloxacin (P Ͻ 0.001), and 0.94 for the combination (P Ͻ 0.001). Although these values are statistically different from 1.0, this difference is not practically important. The correlations between AUIC and predicted AUC/MIC values are shown in Fig. 2A to C. This analysis supports the hypothesis that AUIC can be predicted from pharmacokinetic and bacterial susceptibility data.
The study design did not allow determination of 24-h AUC/ MIC ratios directly; however, simulations were used to evaluate 24-h AUC/MIC and time above EC 50 values, as shown in Table 4 . Time above EC 50 was less than 50% for cefotaxime against the two Pseudomonas test isolates and one isolate of S. aureus. These isolates also were associated with comparatively low AUC/MIC. Further research is needed to refine time above MIC and AUC/MIC targets for ofloxacin and cefotaxime for a variety of infections. At present, optimizing AUC/ MIC appears most important for fluoroquinolones and optimizing time above MIC appears most important for ␤-lactam agents (2, 3, 7) . Figure 3 shows the mean and range of values for the 10 test isolates. The mean values ranged from Ϫ0.033 to 0.067, and all values were consistent with additivity.
DISCUSSION
Cefotaxime PK characteristics were similar to those previously reported (27) . The mean CL T of cefotaxime was reported to be 0.229 liters/kg/h. In our study, the CL T of cefotaxime was 0.236 liters/kg/h. The mean CL T of ofloxacin in our study was 0.143 liters/kg/h. Previous studies have reported more rapid CL T s for ofloxacin, ranging from 0.187 to 0.217 liters/kg/h for a 400-mg intravenous dose (9, 10) . Unlike the previous studies, the present study included female subjects. However, after correction for body weight, CL T was similar in males and females.
In this study, the EC 50 s for both cefotaxime and ofloxacin were highly correlated with MICs against the test organisms. This finding is expected, since the uSIT measurement is similar to a MIC test when the starting concentration of the serum ultrafiltrate sample is known (18, 26) . The only difference is that the medium consists of as much as 50% serum ultrafiltrate, which contains only free drug. Serum ultrafiltrate was used in the present study to avoid the inhibitory effects of serum due to complement and other factors. In order to inactivate complement, serum may also be heated to 50°C for 0.5 to 2 h. This procedure was not feasible in our study, since cefotaxime is unstable under these temperature conditions. Although ultrafiltration removes most of the serum factors that affect these tests, some factors that enhance (17) or inhibit antimicrobial effects remain present.
Several factors contribute to the predictability of uSIT and AUIC. The mean log ratio of AUIC to predicted AUC/MIC was 1.03, showing excellent agreement. Cefotaxime exhibits protein binding ranging from 27 to 38% (22) . This binding would tend to reduce the measured AUIC, since only free drug is active. In contrast, the active metabolite desacetylcefotaxime may contribute to the activity of cefotaxime (14), thereby increasing the AUIC. Ofloxacin has slightly higher protein binding, 47 to 50% (19) , and this may account for the lower mean log ratio (0.899) of AUIC to predicted AUC/MIC. Ofloxacin does not have any active metabolites to offset the effect of protein binding. As expected, the mean log ratio of the combination was between the values found for ofloxacin and cefotaxime. The log ratio of 0.94 for the combination supports an additive antimicrobial interaction.
Areas under the bactericidal curve and AUICs have been previously used to compare different antimicrobial agents (1). This comparison is logical for fluoroquinolones, because the primary parameter that predicts efficacy is AUC/MIC (2, 7). AUC/MIC is theoretically similar to AUIC (25) . For cefotaxime and other ␤-lactam agents, time above MIC is the primary PD parameter of interest (2, 3) . Time above MIC evolved from in vitro studies and animal studies in which dosage intervals varied widely. However, if dosage intervals are designed rationally, and time above MIC is sufficient, the AUC/MIC or AUIC also becomes an important predictor of efficacy. In subsets of patients for whom time above MIC exceeds 80%, AUC/MIC still predicts efficacy (8) .
In previous studies, 24-h AUC/MIC was shown to be predictive of antibacterial efficacy for ciprofloxacin in the treatment of nosocomial lower respiratory tract infections (7). The present study was primarily designed to study the type of PD interaction between ofloxacin and cefotaxime. The range of cefotaxime-ofloxacin concentration ratios was maximized by collecting blood samples over a 14-h period. uSITs were collected during two dosing intervals, but the times selected were not sufficient to allow determination of AUIC for one full dosing interval. Consequently, the measured 24-h AUIC could not be determined. Table 3 provides the 14-h AUICs for the three drug regimens. These data can be used to compare relative activities, since cefotaxime and ofloxacin were administered with identical time schedules for the single and combination regimens.
Predicted 24-h AUC/MIC was calculated by the PK-PD parameter estimates and assuming an additive PD interaction. These data can be used to demonstrate the strengths and weaknesses of the single drugs and of the combination regimen. Based on retrospective analysis, an AUC/MIC of 125 to 250 was associated with good clinical and microbiologic outcomes of patients with suspected nosocomial pneumonia treated with ciprofloxacin (7). This AUC/MIC range corresponds to an average concentration of 5 to 10 times that of the MIC. Similar targets have not been established for cefotaxime and ofloxacin or for other infections in humans. Moreover, AUC/MIC breakpoints have not been evaluated for any combination antimicrobial regimen in a clinical trial.
Desacetylcefotaxime was not considered in our PD model. If this metabolite had contributed significantly to the activity of cefotaxime, a lower EC 50 estimate for cefotaxime monotherapy would be expected. In fact, there was excellent agreement between the EC 50 s estimated from the model and the MIC of cefotaxime for each pathogen. Since desacetylcefotaxime did not appear to explain a substantial portion of the of the activity, we chose not to continue the analysis with a more complex model. A three-drug model would introduce additional problems that were not encountered with the two-drug model. We used predicted drug concentrations rather than observed concentrations to smooth random errors. Desacetylcefotaxime cannot be modeled with the available data. The FIC index, on which our model was based, has not been used extensively for more than two drugs in combination, and such use would be complicated by any interaction between cefotaxime and desacetylcefotaxime. The same limitations would apply to any model that we would have chosen. Considering the problems that would result from a more-complex threedrug model and the lack of evidence supporting a contribution of desacetylcefotaxime to the overall activity, we used the simpler two-drug model. In this study, the combination of ofloxacin and cefotaxime was found to exhibit additive antibacterial effects. Previous reports for patients and in vitro results have suggested that this combination may be synergistic (13) . More than 80% of grampositive and gram-negative isolates were characterized as exhibiting synergy or partial synergy. However, unusual methods for assessing the results were employed. FIC was defined as [ofloxacin]/MIC of ofloxacin plus [cefotaxime-desacetylcefotaxime]/MIC for cefotaxime-desacetylcefotaxime (13) . For, example when the MIC of cefotaxim-desacetylcefotaxime was 16, this meant that the test organism was inhibited by 16 g of cefotaxime plus 16 g of desacetylcefotaxime per ml, 1:1 ratio of desacetylcefotaxime to cefotaxime. Our results show that this ratio occurs around 4 to 5 h following a cefotaxime dose. In conclusion, the combination of cefotaxime and ofloxacin did not exhibit any PK interactions, and the PD interaction was additive. This combination exhibited excellent activity against representative isolates of S. aureus, S. pneumoniae, E. cloacae, and K. pneumoniae. In contrast, the activity of this combination against representative strains of P. aeruginosa was suboptimal, primarily because the two agents had minimal activity against the selected strains of P. aeruginosa. 
